Detection of serum and tissue miR-421 in patients with prostate cancer and its diagnostic significance
10.13315/j.cnki.cjcep.2018.06.005
- VernacularTitle:前列腺癌患者血清和组织中miR-421的表达及临床意义
- Author:
Xiao-Juan HUANG
1
;
Li ZHANG
;
Ling-Fan XU
;
Gui-Fang HE
;
Lu-Lu ZHENG
;
Chao-Zhao LIANG
;
Yu YIN
Author Information
1. 安徽医科大学病理学教研室
- Keywords:
prostate neoplasms;
prostatic hyperplasia;
miR-421
- From:
Chinese Journal of Clinical and Experimental Pathology
2018;34(6):610-614
- CountryChina
- Language:Chinese
-
Abstract:
Purpose To detect the expression of miR-421 in serum and tissues of prostate cancer ( PCa) and its clinical value inPCa. Methods 62 cases of PCa and 46 cases of benign prostatic hyperplasia (BPH) were enrolled in the Department of Urology, the First Affiliated Hospital of Anhui Medical Universi-ty from December 2015 to December 2016. Another 42 cases of paraffin-embedded sections of PCa and 37 cases of BPH were al-so used in this study. The expression of miR-421 in serum was detected by real-time PCR (qRT-PCR). The expression of miR-421 in tissues was detected by in situ hybridization. Results The expression of miR-421 in serum of patients with PCa and BPH was ( 2. 52 ± 1. 70 ) and ( 0. 82 ± 0. 65 ), respectively. Compared with the expression of BPH, the expression of miR- 421 in serum of PCa was increased (P＜0. 05). The expression of miR-421 in serum and tissues of patients with PCa was corre-lated with Gleason score, TNM clinical stage, and bone metasta-ses (P＜0. 05). It was not related to the patient's age, preop-erative PSA level and other factors ( P＞0. 05). Conclusion miR-421 is more abundant in PCa patients than that in patients with benign prostatic hyperplasia, and is expected to become a diagnostic marker for PCa.
